<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562819</url>
  </required_header>
  <id_info>
    <org_study_id>D5161R00003</org_study_id>
    <nct_id>NCT03562819</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).</brief_title>
  <acronym>CONCORDANCE</acronym>
  <official_title>An Observational, Multicentre, Prospective Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, prospective, study of EGFR )Epidermal Growth Factor Receptor) mutation
      status in advanced NSCLC (Non-small cell lung cancer)patients (locally advanced and/or
      metastatic disease) with adenocarcinoma histology proposed to be conducted at 15 sites from
      different geographical regions across India. The study targets to enrol 268 patients over a
      period of 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, prospective, study of EGFR mutation status in advanced NSCLC patients
      (locally advanced and/or metastatic disease) with adenocarcinoma histology proposed to be
      conducted at 15 sites from different geographical regions across India. The study targets to
      enrol 268 patients over a period of 6 months. The study will enroll patients with
      histologically confirmed, systemic treatment naïve adenocarcinoma metastatic cancer (stage
      IV). This will be a single visit study. No study medication will be prescribed or
      administered as a part of study procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the level of concordance between EGFR mutation status</measure>
    <time_frame>1 Day</time_frame>
    <description>by tissue and plasma based testing in terms of Overall Concordance, Sensitivity, specificity, Positive predictive value &amp; negative predictive value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the frequency of T790M mutation among study patients.</measure>
    <time_frame>1 Day</time_frame>
    <description>Frequency and percentage of TKI treatment naïve NSCLC patients with T790M mutation will be provided.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">268</enrollment>
  <condition>NSCLC (Non-small Cell Lung Cancer)</condition>
  <arm_group>
    <arm_group_label>NSCLC</arm_group_label>
    <description>Non-small cell lung cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC (Non-small cell lung cancer)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who provide written informed consent

          2. Patients aged 18 years and older

          3. Newly diagnosed patients with Metastatic (stage IV) NSCLC.

          4. Histologically confirmed Adenocarcinoma NSCLC patient as per tissue biopsy and Tissue
             sample sent for EGFR mutation analysis OR result for EGFR mutation test is available
             from last 28 days from the date of enrolment.

          5. Patient should be naïve for any systemic treatment (i.e. no chemotherapy or EGFR-TKI)

        Exclusion Criteria:

          1. Patient with any medical condition that, in the opinion of the investigator, would
             interfere with outcome of the study

          2. Patient participating in any other interventional clinical study/trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reserch Site</name>
      <address>
        <city>Punjab</city>
        <state>Chandigarh</state>
        <zip>160055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kerala</city>
        <state>Kozhikode</state>
        <zip>673601</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maharashtra</city>
        <state>Mumbai</state>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telanagana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bangal</state>
        <zip>700160</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5161R00003&amp;amp;attachmentIdentifier=dfb6fc8b-84d3-4b83-87af-01a058f7a79e&amp;amp;fileName=Concordance_CSR_V1.0_25Mar2020_Synopsys.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermal Growth Factor Receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

